© Copyright 2017 Sense Biodetection Limited. Company Registration: 08624309. All rights reserved.
Consultant Senior Scientist
Chief Executive Officer
Chief Development Officer
Assay Development Scientist
Medical Device Engineer
Harry has extensive experience in the management of high growth businesses in the life sciences field, having held a number of senior roles in start-up companies.
In addition to his position at Sense, he is also the Research Development Director at Imperial College’s Institute of Biomedical Engineering, where he coordinates multidisciplinary research initiatives in the medical technology field, promoting translation through collaboration with clinical investigators, Imperial Innovations and Med-Tech companies.
Previously, Harry was Director of Business Development and Company Secretary at Oxford BioTherapeutics, an emerging biotech company located in Oxford, UK and San Jose, CA, focused on cancer target / biomarker discovery and the development of novel antibody-based drugs for cancer. During five years at the company he completed numerous major collaboration and licensing agreements with global biopharmaceutical and diagnostics companies (including GSK, Sanofi, Amgen, BMS, Seattle Genetics, Alere & Menarini).
In his earlier career as a research scientist, Harry completed a PhD and post-doctoral research on the industrial application of thermostable enzymes at the University of Bath and worked for companies in the fields of genomics, biomanufacturing and scientific software development. Harry has an MBA from Cranfield School of Management.
Ralph has over 15 years’ experience of the design, development and manufacture of medical devices both in industry and through consulting to some of the worlds leading pharmaceutical and diagnostic companies. He is a degree qualified designer and engineer and has managed development programmes across many areas of the medical device industry.
He was formerly Head of Development at a startup company manufacturing novel drug delivery devices. Here he ran the engineering team and led the successful design and development of a number of products in a role overseeing both internal and key client projects.
His recent experience includes working as a Senior Consultant in the Medical Technology Division of world leading product development specialists Cambridge Consultants.
Through these roles he has developed a proven track record of creating novel intellectual property as well as extensive experience of managing teams through product development and transfer to manufacture, he also has a wide ranging knowledge of industry regulation and ISO 13485 compliant quality systems.
As CDO he is responsible for overseeing the development of Sense’s commercial product ranges.
Chris is an experienced Biomedical Scientist who holds a Ph.D. in Molecular Medicine from Trinity College Dublin. Following his undergraduate studies he relocated to the United States to work as a Research Assistant in the world renowned research institute, Cold Spring Harbour Laboratory. Chris worked for a number of years in the laboratory of Professor Ira Hall and was involved in studying an important, newly appreciated form of genetic variation.
Following this, Chris returned to Ireland to accept a scholarship at Trinity College Dublin. During his Ph.D. and Postdoctoral studies in the Cancer Epigenetic Laboratory, he worked towards gaining insight into the molecular basis of a number of human cancers thought to be driven by epigenetic deregulation.
Chris has significant scientific and laboratory experience and is an expert in 'omic' technologies including gene expression microarrays, CGH DNA microarrays and in Next Generation Sequencing technologies. He has also authored a number of high impact publications in leading international journals including Nature journals and PNAS.
As Consultant Senior Scientist to Sense, Chris is responsible for innovating and researching new assays to enable the company’s groundbreaking products.
Daisy is a graduate of St. Hilda’s college at the University of Oxford, with a Masters in Molecular and Cellular Biochemistry. Her master’s year project was completed at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences as part of Dr Claire Edwards group. Her work was focused on investigating the mechanisms underlying the antineoplastic effects of ATP on metastatic prostate cancer, in particular the interaction of ATP with the P2X class of purinergic receptors.
Subsequently Daisy studied at the University of Strathclyde for a Masters in Forensic Science, during which she undertook a three-month placement at LGC. At LGC Daisy worked within the DNA services team to validate a novel STR PCR DNA profiling kit for use in paternity testing cases.
Daisy’s work within the team is focused on developing and testing the company’s novel molecular diagnostic assays.
David has several years' industry experience successfully developing novel molecular and biochemical techniques in the field of clinical diagnostics. He has been responsible for significant innovation in methods that are core to Sense’s proprietary technologies and as Senior Biochemist also maintains responsibility for several aspects of laboratory operations.
Prior to his career in industry David was a graduate of the University of York with a BSc in Biochemistry. His honours project was undertaken in the laboratory of Dr. Alison Parkin at the University’s Department of Chemistry and in collaboration with the highly respected York Structural Biology Laboratory (YSBL). The main focus of his honours project was in developing a multidisciplinary approach to studying the electrochemical and structural properties of hydrogenase enzymes for use in the hydrogen fuel cell industry.
Steven is a graduate from the University of York with an B.Sc. Hons degree in Biochemistry. During his final year project, Steven worked in the Centre of Immunology and Infection in York, under the supervision of Dr. Marjan van der Woude. His project was aimed at investigating the mechanisms underlying epigenetic phase variation within Salmonella, particularly the relationship between DNA binding proteins, OxyR and Dam.
Subsequently, Steven undertook an industrial placement at the Institute of Cancer Therapeutics, Bradford. There, in collaboration with Dr. Paul Loadman, Steven focussed on the development of a water soluble analogue of the matrix metalloproteinase targeting cancer therapeutic ICT2588.
Steven has a broad experience of the novel technologies behind the companies platform, he brings particular knowledge of bio-production and associated techniques.
Kirsty is a graduate of the University of St Andrews with a BSc in Cell Biology. Her undergraduate dissertation was undertaken in the laboratory of Dr Tracey Gloster in the Biomedical Sciences Research Complex, and focussed on creating the optimum expression conditions of the Drosophila Melanogaster gene LD33103 in both E.coli and Drosophila melanogaster cell lines.
She has also recently finished a Masters in Biomedical Sciences (specialism molecular genetics) at the University of Glasgow, where she has completed two research projects which involved using the gene editing technique CRISPR in order to make precise modifications in certain genes. Specifically, CRISPR was used to create the fusion genes Mll-Af9 and Aml1-Eto in mice to explore the genetic changes in Leukemia during a research project carried out in the laboratory of Dr Karen Keeshan at the Paul O'Gorman Leukemia Research Centre. Her second project was carried out in the laboratory of Professor Julian Dow at the Institute of Molecular, Cell and Systems Biology and used CRISPR to tag the Drosophila melanogaster ion transporter genes dPrestin and dZip10 with a marker in order to determine their membrane location.
Kirsty's work at Sense is focused on the molecular aspects of the development of the companies novel diagnostic assays.
Gemma is an experienced Molecular Biologist with a Ph.D. in Molecular Microbiology from the University of Birmingham.
Following undergraduate studies in Microbiology at the University of Nottingham, Gemma moved to the University of Birmingham to investigate the relationship between motility, stress and pathogenicity in Campylobacter and Helicobacter species.
Gemma has gone on to forge a highly successful career in the field of molecular diagnostics gaining a wide range of experience in diagnostic assay and device development, validation and production across various roles at companies including Enigma Diagnostics Ltd. She also has significant experience of ISO13485 compliant quality systems and production of molecular diagnostic assays in a GMP environment.
At Sense Gemma brings leadership to the Company’s molecular development activities interfacing across the molecular and engineering teams.
Gemma is a graduate of Churchill College at the University of Cambridge, with a Masters of Research in Sensor Technologies.
Her master's year project was completed in the Laser Analytics Group (LAG) under the supervision of Professor Clemens Kaminski where her work was focused on creating methods to improve production of Newcastle Disease Virus and Influenza for use in cancer treatments and vaccines using super-resolution imaging and machine learning techniques. She was also involved in the creation of a low-cost, open source Optical Projection Tomography Microscope.
Gemma’s role at Sense as a Medical Device Engineer is focused on utilising her broad range of engineering skills to progress Sense’s device technologies in order to have a significant impact on clinical diagnostics in the real world.